Table 4.
ORs for severe COVID-19 (hospitalisation or death) within 30 days after the index date
| Unadjusted | Multivariable model 1* | Multivariable model 2† | |
|---|---|---|---|
| Primary analysis | |||
| Any outpatient treatment vs no outpatient treatment | 0·10 (0·05–0·21) | 0·12 (0·05–0·25) | 0·13 (0·06–0·28) |
| Secondary analyses | |||
| Nirmatrelvir–ritonavir vs no outpatient treatment | 0·06 (0·02–0·17) | 0·08 (0·03–0·24) | 0·09 (0·03–0·27) |
| Monoclonal antibodies vs no outpatient treatment | 0·23 (0·09–0·60) | 0·20 (0·07–0·54) | 0·21 (0·08–0·57) |
| Nirmatrelvir–ritonavir vs no outpatient treatment and all other treatments | 0·08 (0·03–0·23) | 0·12 (0·04–0·34) | 0·13 (0·04–0·37) |
| Monoclonal antibodies vs no outpatient treatment and all other treatments | 0·52 (0·20–1·32) | 0·35 (0·13–0·97) | 0·35 (0·13–0·99) |
| Nirmatrelvir–ritonavir vs monoclonal antibodies | 0·26 (0·07–1·00) | 0·46 (0·11–1·97) | 0·43 (0·10–1·86) |
Data are OR (95% CI). OR=odds ratio.
*
Model 1 was adjusted for continuous age, continuous Charlson Comorbidity Index, continuous estimated glomerular filtration rate, and race.
†
Model 2 was adjusted for the covariates listed in Model 1 and zip code area median household income.